Boris Julg1,2, Dan H Barouch1,2. 1. Ragon Institute of MGH, MIT and Harvard, Cambridge. 2. Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA.
Abstract
PURPOSE OF REVIEW: In the absence of a protective vaccine against HIV-1, passive immunization using novel broadly neutralizing antibodies (bNAbs) is an attractive concept for HIV-1 prevention. Here, we summarize the results of preclinical and clinical studies of bNAbs, discuss strategies for optimizing bNAb efficacy and lay out current pathways for the development of bNAbs as prophylaxis. RECENT FINDINGS: Passive transfer of second-generation bNAbs results inpotent protection against infection in preclinical animal models. Furthermore, multiple bNAbs targeting different epitopes on the HIV-1 envelope trimer are in clinical evaluation and have demonstrated favorable safety profiles and robust antiviral activity in chronically infected individuals. The confirmation that passive immunization with bNAb(s) will prevent HIV-1 acquisition in humans is pending and the focus of ongoing investigations. Given the global diversity of HIV-1, bNAb combinations or multispecific antibodies will most likely be required to produce the necessary breadth for effective protection. SUMMARY: Encouraging results from preclinical and clinical studies support the development of bNAbs for prevention and a number of antibodies with exceptional breadth and potency are available for clinical evaluation. Further optimization of viral coverage and antibody half-life will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention strategies.
PURPOSE OF REVIEW: In the absence of a protective vaccine against HIV-1, passive immunization using novel broadly neutralizing antibodies (bNAbs) is an attractive concept for HIV-1 prevention. Here, we summarize the results of preclinical and clinical studies of bNAbs, discuss strategies for optimizing bNAb efficacy and lay out current pathways for the development of bNAbs as prophylaxis. RECENT FINDINGS: Passive transfer of second-generation bNAbs results inpotent protection against infection in preclinical animal models. Furthermore, multiple bNAbs targeting different epitopes on the HIV-1 envelope trimer are in clinical evaluation and have demonstrated favorable safety profiles and robust antiviral activity in chronically infected individuals. The confirmation that passive immunization with bNAb(s) will prevent HIV-1 acquisition in humans is pending and the focus of ongoing investigations. Given the global diversity of HIV-1, bNAb combinations or multispecific antibodies will most likely be required to produce the necessary breadth for effective protection. SUMMARY: Encouraging results from preclinical and clinical studies support the development of bNAbs for prevention and a number of antibodies with exceptional breadth and potency are available for clinical evaluation. Further optimization of viral coverage and antibody half-life will accelerate the clinical implementation of bNAbs as a critical tool for HIV-1 prevention strategies.
Authors: Rebecca T van Dorsten; Bronwen E Lambson; Constantinos Kurt Wibmer; Marc S Weinberg; Penny L Moore; Lynn Morris Journal: J Virol Date: 2020-01-06 Impact factor: 5.103
Authors: Philipp Schommers; Henning Gruell; Morgan E Abernathy; My-Kim Tran; Adam S Dingens; Harry B Gristick; Christopher O Barnes; Till Schoofs; Maike Schlotz; Kanika Vanshylla; Christoph Kreer; Daniela Weiland; Udo Holtick; Christof Scheid; Markus M Valter; Marit J van Gils; Rogier W Sanders; Jörg J Vehreschild; Oliver A Cornely; Clara Lehmann; Gerd Fätkenheuer; Michael S Seaman; Jesse D Bloom; Pamela J Bjorkman; Florian Klein Journal: Cell Date: 2020-01-30 Impact factor: 41.582
Authors: Eytan Herzig; Kaman Chan Kim; Thomas A Packard; Noam Vardi; Roland Schwarzer; Andrea Gramatica; Steven G Deeks; Steven R Williams; Kyle Landgraf; Nigel Killeen; David W Martin; Leor S Weinberger; Warner C Greene Journal: Cell Date: 2019-10-24 Impact factor: 41.582
Authors: Rena D Astronomo; Maria P Lemos; Sandeep R Narpala; Julie Czartoski; Lamar Ballweber Fleming; Kelly E Seaton; Madhu Prabhakaran; Yunda Huang; Yiwen Lu; Katharine Westerberg; Lily Zhang; Mary K Gross; John Hural; Hong-Van Tieu; Lindsey R Baden; Scott Hammer; Ian Frank; Christina Ochsenbauer; Nicole Grunenberg; Julie E Ledgerwood; Kenneth Mayer; Georgia Tomaras; Adrian B McDermott; M Juliana McElrath Journal: J Clin Invest Date: 2021-08-16 Impact factor: 19.456
Authors: Ann M Carias; Jeffrey R Schneider; Patrick Madden; Ramon Lorenzo-Redondo; Mariluz Araínga; Amarendra Pegu; Gianguido C Cianci; Danijela Maric; Francois Villinger; John R Mascola; Ronald S Veazey; Thomas J Hope Journal: J Immunol Date: 2021-06-23 Impact factor: 5.426